Biodexa Pharmaceuticals (BDRX) Competitors $1.37 -0.28 (-16.97%) As of 02:33 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. TKNO, SEPN, ENGN, AVIR, ESPR, CADL, ACB, PVLA, IMMP, and OLMAShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Alpha Teknova (TKNO), Septerna (SEPN), enGene (ENGN), Atea Pharmaceuticals (AVIR), Esperion Therapeutics (ESPR), Candel Therapeutics (CADL), Aurora Cannabis (ACB), Palvella Therapeutics (PVLA), Immutep (IMMP), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Alpha Teknova Septerna enGene Atea Pharmaceuticals Esperion Therapeutics Candel Therapeutics Aurora Cannabis Palvella Therapeutics Immutep Olema Pharmaceuticals Biodexa Pharmaceuticals (NASDAQ:BDRX) and Alpha Teknova (NASDAQ:TKNO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk, earnings and community ranking. Which has more risk & volatility, BDRX or TKNO? Biodexa Pharmaceuticals has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Alpha Teknova has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500. Does the media refer more to BDRX or TKNO? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Alpha Teknova. MarketBeat recorded 2 mentions for Biodexa Pharmaceuticals and 1 mentions for Alpha Teknova. Alpha Teknova's average media sentiment score of 1.80 beat Biodexa Pharmaceuticals' score of 0.94 indicating that Alpha Teknova is being referred to more favorably in the news media. Company Overall Sentiment Biodexa Pharmaceuticals Positive Alpha Teknova Very Positive Do insiders and institutionals hold more shares of BDRX or TKNO? 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are owned by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Comparatively, 15.2% of Alpha Teknova shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend BDRX or TKNO? Alpha Teknova has a consensus price target of $8.50, indicating a potential upside of 48.08%. Given Alpha Teknova's stronger consensus rating and higher probable upside, analysts clearly believe Alpha Teknova is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alpha Teknova 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer BDRX or TKNO? Alpha Teknova received 8 more outperform votes than Biodexa Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Biodexa Pharmaceuticals an outperform vote while only 39.13% of users gave Alpha Teknova an outperform vote. CompanyUnderperformOutperformBiodexa PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesAlpha TeknovaOutperform Votes939.13% Underperform Votes1460.87% Which has preferable valuation and earnings, BDRX or TKNO? Biodexa Pharmaceuticals has higher earnings, but lower revenue than Alpha Teknova. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiodexa Pharmaceuticals$83K603.20-$7.66MN/AN/AAlpha Teknova$37.75M8.13-$36.78M-$0.59-9.73 Is BDRX or TKNO more profitable? Biodexa Pharmaceuticals has a net margin of 0.00% compared to Alpha Teknova's net margin of -87.17%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Alpha Teknova's return on equity.Company Net Margins Return on Equity Return on Assets Biodexa PharmaceuticalsN/A N/A N/A Alpha Teknova -87.17%-35.30%-24.52% SummaryBiodexa Pharmaceuticals beats Alpha Teknova on 9 of the 16 factors compared between the two stocks. Remove Ads Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.07M$6.31B$5.32B$7.56BDividend YieldN/A3.23%5.11%4.33%P/E RatioN/A6.7821.7717.81Price / Sales603.20222.80378.2693.59Price / CashN/A65.6738.1534.64Price / Book0.035.826.443.99Net Income-$7.66M$141.86M$3.20B$247.23M7 Day Performance-2.84%8.99%6.42%7.24%1 Month Performance-27.89%-12.57%-8.66%-6.26%1 Year PerformanceN/A-12.38%10.27%-0.18% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.7903 of 5 stars$1.37-17.0%N/AN/A$50.07M$83,000.000.0020Gap DownTKNOAlpha Teknova1.7504 of 5 stars$4.51-3.6%$8.50+88.5%+135.3%$241.00M$37.75M-6.09240Positive NewsSEPNSepterna2.0698 of 5 stars$5.38-1.8%$33.00+513.4%N/A$239.10M$1.08M0.00N/APositive NewsENGNenGene3.0689 of 5 stars$4.68+4.0%$25.22+438.9%-74.0%$238.57MN/A-8.0731AVIRAtea Pharmaceuticals2.5022 of 5 stars$2.78-0.4%$6.88+147.5%-21.8%$237.76MN/A-1.3470ESPREsperion Therapeutics3.6505 of 5 stars$1.20-2.4%$6.75+462.5%-53.3%$237.42M$332.31M-1.88200Gap UpCADLCandel Therapeutics2.2768 of 5 stars$4.84+0.4%$21.00+333.9%-22.4%$228.62M$120,000.00-2.8060Short Interest ↑ACBAurora Cannabis0.535 of 5 stars$4.05+1.0%N/A-35.6%$225.70M$320.81M81.021,340PVLAPalvella Therapeutics3.6173 of 5 stars$20.07-16.3%$43.50+116.7%N/A$221.15M$42.81M-1.66N/AAnalyst RevisionIMMPImmutep1.6279 of 5 stars$1.42-5.3%$8.50+498.6%-40.2%$218.34M$5.14M0.002,021Gap DownOLMAOlema Pharmaceuticals2.9218 of 5 stars$3.18-2.2%$27.67+770.0%-62.6%$217.30MN/A-1.4570Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Alpha Teknova Competitors Septerna Competitors enGene Competitors Atea Pharmaceuticals Competitors Esperion Therapeutics Competitors Candel Therapeutics Competitors Aurora Cannabis Competitors Palvella Therapeutics Competitors Immutep Competitors Olema Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredFmr. Presidential Advisor’s Urgent Warning: “Exit Tech Now!”A former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BDRX Stock Free BDRX Stock Alerts